Scholarlink

<p><i>Lactobacillus</i> species have been extensively studied for their beneficial effects on vaginal health, but recent evidence highlights their broader therapeutic potential in gut homeostasis. Building on our prior genomic analysis of 3,324 gut bacterial strains, we selected <i>Lactobacillus gasseri</i> TF08-1 for inflammatory bowel disease intervention. In a DSS-induced mouse model, <i>L. gasseri</i> TF08-1 administration produced marked clinical improvements, including attenuated body weight loss, reduced disease activity index (DAI), and restored colon length. Histological analysis confirmed its protective effects on intestinal mucosal integrity. Additionally, <i>L. gasseri</i> TF08-1 alleviated systemic and colonic inflammation by regulating the expression of pro- and anti-inflammatory cytokines. Metagenomic analysis revealed that <i>L. gasseri</i> TF08-1 altered gut microbiota composition, increasing microbial diversity and restoring key genera associated with gut health. These results suggest that <i>L. gasseri</i> TF08-1 holds promise as a therapeutic candidate for inflammatory bowel disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactobacillus gasseri TF08-1 Alleviates DSS-Induced Acute Colitis by Protecting Intestinal Epithelial Barrier

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Qianyue Xu,
  • Mengmeng Wang,
  • Haoyu Wang,
  • Zhinan Wu,
  • Xiaofang Li,
  • Jingxi Sun,
  • Zizhen Yang,
  • Ningning He,
  • Yang Sun,
  • Haifeng Zhang,
  • Yiyi Zhong,
  • Liang Xiao,
  • Shangyong Li,
  • Yuanqiang Zou

摘要

Lactobacillus species have been extensively studied for their beneficial effects on vaginal health, but recent evidence highlights their broader therapeutic potential in gut homeostasis. Building on our prior genomic analysis of 3,324 gut bacterial strains, we selected Lactobacillus gasseri TF08-1 for inflammatory bowel disease intervention. In a DSS-induced mouse model, L. gasseri TF08-1 administration produced marked clinical improvements, including attenuated body weight loss, reduced disease activity index (DAI), and restored colon length. Histological analysis confirmed its protective effects on intestinal mucosal integrity. Additionally, L. gasseri TF08-1 alleviated systemic and colonic inflammation by regulating the expression of pro- and anti-inflammatory cytokines. Metagenomic analysis revealed that L. gasseri TF08-1 altered gut microbiota composition, increasing microbial diversity and restoring key genera associated with gut health. These results suggest that L. gasseri TF08-1 holds promise as a therapeutic candidate for inflammatory bowel disease.